Company intelligence / Profile preview

Cyclenium Pharma

Ownership: Private
Development stage: Preclinical

Overview

Cyclenium Pharma has developed a proprietary next-generation macrocyclic drug discovery platform (CMRT™) and is focused on discovering and developing small-molecule macrocycles for challenging disease targets. The company operates both internal R&D programs and collaborative projects with academic, non-profit, pharmaceutical, and biotechnology partners. Its pipeline includes preclinical programs in oncology, infectious diseases, and inflammation/pain. No clinical results have been reported publicly.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Small moleculeMacrocyclesMacrocyclic compounds
Industry: Biotech

Partnerships

Collaborations with academic institutions, non-profits, pharmaceutical and biotechnology companies worldwide. Specific partners not named.

Beyond the preview

Go deeper on Cyclenium Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclenium Pharma.

Explore the full profile